SUPN Reports Mixed Results in ADHD
SUPN reported mixed positive results today for its final phase 3 trial for SPN-812 in attention deficit hyperactivity disorder (ADHD).*...
${alertText}
Want unlimited access? Try Pro free for 7 days.
SUPN Reports Mixed Results in ADHD
ALDX Presents Positive Ph3 Data in Allergic Conjunctivitis
Imminent Key Cystic Fibrosis Read-Outs for Proteostatis
UROV's Vibegron Imminent Phase 3 Readout In Overactive Bladder Has a Good Chance of Success
Big/Suspected Movers FAQ/User Guide
Quarterly Big Mover Biotech Stocks To Watch
Q2 2023 Product Revenue Analyses
BPIQ Q2 2023 Biotech Hedge Fund (13F) Analysis
SYFOVRE (APLS) vs. IZERVAY (Astellas)
BIIB & SAGE: Zuranolone
Apellis Pharmaceuticals (APLS)
Our platform helps you uncover your next biotech investment opportunity